<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430820</url>
  </required_header>
  <id_info>
    <org_study_id>P060201</org_study_id>
    <nct_id>NCT00430820</nct_id>
  </id_info>
  <brief_title>Discovery of New Circulating Biomarkers of Coronary Atherosclerosis</brief_title>
  <official_title>Discovery of New Circulating Biomarkers of Coronary Atherosclerosis Using Differential Proteomics: the BIOmarkers of CORonary Events (BIOCORE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fédération Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that differential proteomic techniques can be used to discover new&#xD;
      circulating biomarkers of coronary atherosclerosis in the blood of patients suffering from&#xD;
      coronary artery disease (either stable or unstable) who will be compared to a group of&#xD;
      patients without coronary artery disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Our hypothesis is that coronary atherosclerosis induces both quantitative and&#xD;
      qualitative modifications of circulating proteins, which can be captured by a differential&#xD;
      proteomic approach applied to serum or plasma samples. Identification of such modifications&#xD;
      in the circulating blood of patients with coronary artery disease (versus patients without&#xD;
      coronary artery disease) and/or of patients with acute coronary syndromes (versus stable&#xD;
      coronary artery disease) may lead to discovery of new biomarkers of coronary atherosclerosis&#xD;
      and of atherosclerotic plaque vulnerability.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objective: Identification of new circulating biomarkers of stable and unstable&#xD;
      coronary artery disease using a new approach of differential proteomics.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Evaluation of the diagnostic value of these new biomarkers for the diagnosis of stable&#xD;
           and unstable coronary artery disease.&#xD;
&#xD;
        -  Comparison of the diagnostic value of these new biomarkers to the diagnostic value of 1)&#xD;
           other validated biomarkers of atherosclerosis (eg, CRP, IL-6, CD40L, markers of&#xD;
           leukocyte activation, …); and 2) of non-invasive measures of arterial function (eg,&#xD;
           carotid artery intima-media thickness, pulse wave velocity, ankle/brachial index, …)&#xD;
&#xD;
        -  Description of the relationship between these new biomarkers and major adverse coronary&#xD;
           events (death, myocardial infarction, revascularization) during a 12-month follow-up.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Uniq center, prospective study. Three groups of patients will be studied. Group 1:&#xD;
      Non-ST-elevation acute myocardial infarction; Group 2: Stable coronary artery disease; Group&#xD;
      3: normal coronary arteries and absence of other detectable atherosclerotic lesions.&#xD;
&#xD;
      A new proteomic approach will be applied to serum and plasma samples obtained 1 month after&#xD;
      the index hospitalisation. This approach includes 3 steps: 1) equalisation of circulating&#xD;
      proteins (expose low-concentration proteins belonging to the &quot;deep-proteome&quot;); 2) Retention&#xD;
      chromatography; and 3) protein separation using 2D-electrophoresis and Surface-Enhanced Laser&#xD;
      Desorption/Ionisation Time-of-Flight (SELDI-TOF).&#xD;
&#xD;
      Biomarkers with the highest diagnostic value will be subsequently identified using&#xD;
      Matrix-Assisted Laser Desorbtion/Ionisation Time-of-Flight (MALDI-TOF) and tandem mass&#xD;
      spectrometry (MS/MS).&#xD;
&#xD;
      Perspectives:&#xD;
&#xD;
      Validation of the diagnostic and prognostic values of the new biomarkers discovered and&#xD;
      identified using the proteomic approach described above will require development of more&#xD;
      straightforward measurement techniques (eg, ELISA), which will be used prospectively or&#xD;
      retrospectively in other cohorts of patients with coronary artery disease. Basic studies will&#xD;
      be performed in parallel, so as to better understand the role of these new biomarkers in the&#xD;
      pathophysiology of atherosclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndromes</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>30 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>30 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>30 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>per intervention</intervention_name>
    <description>per intervention</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biomarqueurs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Identification de nouveaux marqueurs circulants de l'athérosclérose coronarienne et de ses&#xD;
        complications par une nouvelle technique de protéomique différentielle.&#xD;
&#xD;
        Identification of new parqueurs circulated in coronary artheriosclerosis and complications&#xD;
        of the new differentiel technicology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group 1 (Non-ST-elevation acute myocardial infarction) :&#xD;
&#xD;
               -  Chest pain less than 48 hours before admission,&#xD;
&#xD;
               -  And modifications of ST-T (no persistent ST elevation) on 12-lead EKG,&#xD;
&#xD;
               -  And elevation of troponin-I &gt;1xN,&#xD;
&#xD;
               -  And presence of ≥1 de novo stenosis(es) &gt;50% located on ≥1 native coronary&#xD;
                  artery(ies) and successfully treated using percutaneous coronary intervention and&#xD;
                  stenting.&#xD;
&#xD;
          -  Group 2 (Stable coronary artery disease) :&#xD;
&#xD;
               -  Documented myocardial ischemia (stable angina or positive stress test)&#xD;
&#xD;
               -  And presence of ≥1 de novo stenosis(es) &gt;50% located on ≥1 native coronary&#xD;
                  artery(ies) and successfully treated using percutaneous coronary intervention and&#xD;
                  stenting.&#xD;
&#xD;
          -  Group 3 (Normal coronary arteries) :&#xD;
&#xD;
               -  No history of coronary artery disease, neurovascular disease or peripheral artery&#xD;
                  disease,&#xD;
&#xD;
               -  And normal coronary angiography performed because of suspected coronary artery&#xD;
                  disease&#xD;
&#xD;
               -  And absence of significant functional or anatomic abnormalities suggestive of&#xD;
                  atherosclerosis on non-invasive arterial studies (measurements of intima-media&#xD;
                  thickness, pulse wave velocity, ankle-brachial index, …).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Group 1 :&#xD;
&#xD;
               -  Preexisting EKG abnormalities (including left bundle branch block) precluding&#xD;
                  accurate assessment of ST-T changes&#xD;
&#xD;
          -  Group 2 :&#xD;
&#xD;
               -  History of acute coronary syndrome&#xD;
&#xD;
          -  Groups 1 and 2:&#xD;
&#xD;
               -  Culprit coronary artery stenosis is a restenosis or a stent thrombosis or is&#xD;
                  located in a bypass graft.&#xD;
&#xD;
          -  All groups :&#xD;
&#xD;
               -  Heart failure (NYHA class ≥II)&#xD;
&#xD;
               -  Left ventricular ejection fraction &lt;50%&#xD;
&#xD;
               -  Severe valvular heart disease requiring surgical or percutaneous therapy&#xD;
&#xD;
               -  History of autoimmune, inflammatory or neoplasia diseases ; or infectious disease&#xD;
                  in the month before admission&#xD;
&#xD;
               -  Life expectancy &lt; 1 year&#xD;
&#xD;
               -  Age &lt;18 years or &gt;80 years&#xD;
&#xD;
               -  Current pregnancy or breast-feeding&#xD;
&#xD;
               -  Homeless or travelers who may not be followed-up&#xD;
&#xD;
               -  Refusal to sign the informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent FELDMAN, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Hopital Bichat, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Duran MC, Mas S, Martin-Ventura JL, Meilhac O, Michel JB, Gallego-Delgado J, Lázaro A, Tuñon J, Egido J, Vivanco F. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics. 2003 Jun;3(6):973-8.</citation>
    <PMID>12833522</PMID>
  </results_reference>
  <results_reference>
    <citation>Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, Jensen ON, Hernandez-Merida S, Tuñón J, Vivanco F, Egido J. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004 Oct 12;110(15):2216-9. Epub 2004 Jul 12.</citation>
    <PMID>15249501</PMID>
  </results_reference>
  <results_reference>
    <citation>Vivanco F, Martín-Ventura JL, Duran MC, Barderas MG, Blanco-Colio L, Dardé VM, Mas S, Meilhac O, Michel JB, Tuñón J, Egido J. Quest for novel cardiovascular biomarkers by proteomic analysis. J Proteome Res. 2005 Jul-Aug;4(4):1181-91. Review.</citation>
    <PMID>16083268</PMID>
  </results_reference>
  <results_reference>
    <citation>Blanco-Colio LM, Martín-Ventura JL, Vivanco F, Michel JB, Meilhac O, Egido J. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res. 2006 Oct 1;72(1):18-29. Epub 2006 May 24. Review.</citation>
    <PMID>16814757</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>February 1, 2007</study_first_submitted>
  <study_first_submitted_qc>February 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2007</study_first_posted>
  <last_update_submitted>December 2, 2010</last_update_submitted>
  <last_update_submitted_qc>December 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Yannick Vacher</name_title>
    <organization>Department Clinical Research of Developppement</organization>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Mass spectrometry</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Acute coronary syndromes</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

